NCT07119905Not yet recruiting
Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital
Source: ClinicalTrials.gov · Last updated 13 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 2 Aug 2025
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Sohag University
- Diseases
- Glaucoma
- NCT number
- NCT07119905
What you commit to
- Study type: Observational
- Planned participants: 80
- From 1 Jun 2026 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of acute angle closure
Other
- Exfoliation glaucoma, pigmentary glaucoma
Who the study is looking for
- Men and women older than 30 years
- Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group)
- Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Hosipital Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.